SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Beasley GM, Petersen RP, Yoo YS. Isolated limb infusion for in-transit malignant melanoma of the extremity: a well tolerated but less effective alternative to hyperthermic isolated limb perfusion. Ann Surg Oncol. 2008; 15: 2195-2205.
  • 2
    Brady MS, Brown K, Patel A, et al. Isolated limb infusion with melphalan and dactinomycin for regional melanoma and soft-tissue sarcoma of the extremity: final report of a phase II clinical trial. Melanoma Res. 2009; 19: 106-111.
  • 3
    Kroon HM, Moncrieff M, Kam PCA, et al. Outcomes following isolated limb infusion for melanoma. A 14-year experience. Ann Surg Oncol. 2008; 15: 3003-3013.
  • 4
    Beasley GM, Caudle A, Petersen RP, et al. A multi-institutional experience of isolated limb infusion: defining response and toxicity in the US. J Am Coll Surg. 2009; 208: 706-715; discussion 715-717.
  • 5
    Moncrieff M, Kroon H, Kam PCA. Isolated limb infusion for advanced soft tissue sarcoma of the extremity. Ann Surg Oncol. 2008; 15: 2749-2756.
  • 6
    Raymond AK, Beasley GM, Broadwater G, et al. Current trends in regional therapy for melanoma: lessons learned from 225 regional chemotherapy treatments between 1995 and 2010 at a single institution. J Am Coll Surg. 2011; 213: 306-316.
  • 7
    Vyas A, Avritscher R, Ensor J, Ross M, Wallace MJ. Isolated limb infusion with cytotoxic agents: a simplified approach for venous access. Cancer. 2010; 116: 459-464.
  • 8
    McMahon N, Cheng TY, Beasley GM, et al. Optimizing melphalan pharmacokinetics in regional melanoma therapy: does correcting for ideal body weight alter regional response or toxicity? Ann Surg Oncol. 2009; 16: 953-961.
  • 9
    Cheng TY, Gruubs E, Abduke-Wahab O, et al. Marked variability of melphalan plasma drug levels during regional hyperthermic isolated limb perfusion. Am J Surg. 2003; 186: 460-467.
  • 10
    Ehrsson H, Eksborg S, Lindfors A. Quantitative determination of melphalan in plasma by liquid chromatography after derivatization with N-acetylcysteine. J Chromatogr. 1986; 380: 222-229.
  • 11
    Beasley GM, Riboh J, Augustine CK, et al. Prospective multicenter phase II trial of systemic ADH-1 in combination with melphalan via isolated limb infusion in patients with advanced extremity melanoma. J Clin Oncol. 2011; 29: 1210-1215.
  • 12
    McMahon N, Beasley G, Sanders G, et al. A phase I study of systemic sorafenib in combination with isolated limb infusion with melphalan (ILI-M) in patients (pts) with locally advanced in-transit melanoma [abstract]. J Clin Oncol. 2009; 27( 15S). Abstract 9065.
  • 13
    Skarsgard LD, Skwarchuk MW, Vinczan A, et al. The cytotoxicity of melphalan and its relationship to pH, hypoxia, and drug uptake. Anticancer Res. 1995; 15: 219-223.
  • 14
    Thompson JF, Anisimov YG, Smithers BM, et al. Microdialysis and response during regional chemotherapy by isolated limb infusion of melphalan for limb malignancies. Br J Cancer. 2001; 85: 157-165.
  • 15
    Prescott DM, Charles HC, Poulson JM, et al. The relationship between intracellular and extracellular pH in the spontaneous canine tumors. Clin Cancer Res. 2000; 6: 2501-2505.